SIMILAR PATTERNS OF AMINO ACIDS FOR 2HYY_C_STIC600_1

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1h4l	CELL DIVISION PROTEIN KINASE 5 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 18 ALA A 31 GLU A 51 VAL A 64 PHE A 82 LEU A 133 ALA A 143	None	0.76A	2hyyC-1h4lA: 23.8	2hyyC-1h4lA: 25.96
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1k9a	CARBOXYL-TERMINAL SRC KINASE (Rattus norvegicus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	7	VAL A 209 ALA A 220 GLU A 236 VAL A 249 THR A 266 GLY A 272 LEU A 321	None	0.66A	2hyyC-1k9aA: 31.3	2hyyC-1k9aA: 30.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1luf	MUSCLE-SPECIFIC TYROSINE KINASE RECEPTOR MUSK (Rattus norvegicus)	PF07714 (Pkinase_Tyr)	7	VAL A 588 ALA A 606 VAL A 638 GLY A 660 LEU A 731 ALA A 741 ASP A 742	None	0.76A	2hyyC-1lufA: 30.2	2hyyC-1lufA: 37.65
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	11	TYR A 272 VAL A 275 ALA A 288 GLU A 305 ILE A 312 VAL A 318 THR A 334 PHE A 336 GLY A 340 LEU A 389 ALA A 399	P16 A 2 (-3.6A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.2A) None P16 A 2 ( 4.7A) P16 A 2 (-3.7A) P16 A 2 ( 4.4A) P16 A 2 (-3.4A) P16 A 2 (-4.4A) P16 A 2 (-3.5A)	0.84A	2hyyC-1opkA: 35.2	2hyyC-1opkA: 99.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1t46	HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL A 603 ALA A 621 GLU A 640 VAL A 654 THR A 670 GLY A 676 LEU A 799 ASP A 810	STI A 3 ( 4.6A) STI A 3 (-3.5A) STI A 3 (-3.6A) STI A 3 (-4.3A) STI A 3 (-3.2A) STI A 3 ( 3.8A) STI A 3 (-4.4A) STI A 3 (-3.9A)	0.55A	2hyyC-1t46A: 29.4	2hyyC-1t46A: 37.22
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1u59	TYROSINE-PROTEIN KINASE ZAP-70 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 352 ALA A 367 GLU A 386 VAL A 399 GLY A 420 LEU A 468	STU A 100 (-4.8A) STU A 100 (-3.2A) None None STU A 100 (-3.5A) STU A 100 (-4.5A)	0.45A	2hyyC-1u59A: 31.0	2hyyC-1u59A: 38.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2buj	SERINE/THREONINE-PRO TEIN KINASE 16 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 34 ALA A 47 GLU A 65 PHE A 100 GLY A 104 LEU A 155 ASP A 166	STU A1301 (-4.8A) STU A1301 (-3.6A) None STU A1301 (-4.5A) STU A1301 ( 4.0A) STU A1301 ( 4.8A) None	0.84A	2hyyC-2bujA: 23.2	2hyyC-2bujA: 23.58
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2dq7	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL X 25 ALA X 37 GLU X 54 VAL X 67 THR X 82 GLY X 88 LEU X 137 ALA X 147	STU X 902 ( 4.8A) STU X 902 (-3.1A) STU X 902 ( 4.4A) None STU X 902 (-4.1A) STU X 902 (-3.5A) STU X 902 (-4.4A) STU X 902 ( 4.1A)	0.65A	2hyyC-2dq7X: 32.6	2hyyC-2dq7X: 46.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2eu9	DUAL SPECIFICITY PROTEIN KINASE CLK3 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 170 ALA A 184 GLU A 201 ILE A 208 VAL A 220 LEU A 290 ALA A 319	None	0.73A	2hyyC-2eu9A: 22.0	2hyyC-2eu9A: 24.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2eu9	DUAL SPECIFICITY PROTEIN KINASE CLK3 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 170 ALA A 184 GLU A 201 VAL A 220 GLY A 240 LEU A 290 ALA A 319	None	1.04A	2hyyC-2eu9A: 22.0	2hyyC-2eu9A: 24.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2h8h	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	7	VAL A 281 ALA A 293 VAL A 323 THR A 338 GLY A 344 LEU A 393 ALA A 403	H8H A 534 (-4.4A) H8H A 534 (-3.2A) None H8H A 534 (-3.1A) H8H A 534 (-3.3A) H8H A 534 (-4.5A) H8H A 534 ( 4.0A)	0.81A	2hyyC-2h8hA: 31.0	2hyyC-2h8hA: 27.56
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hck	HEMATOPOETIC CELL KINASE HCK (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	7	ALA A 293 VAL A 323 THR A 338 PHE A 340 GLY A 344 LEU A 393 ALA A 403	QUE A 1 (-3.5A) None QUE A 1 (-3.3A) QUE A 1 (-4.2A) QUE A 1 (-3.0A) QUE A 1 (-4.4A) QUE A 1 ( 4.5A)	0.63A	2hyyC-2hckA: 30.4	2hyyC-2hckA: 30.72
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hck	HEMATOPOETIC CELL KINASE HCK (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	7	VAL A 281 ALA A 293 VAL A 323 THR A 338 PHE A 340 LEU A 393 ALA A 403	QUE A 1 ( 4.8A) QUE A 1 (-3.5A) None QUE A 1 (-3.3A) QUE A 1 (-4.2A) QUE A 1 (-4.4A) QUE A 1 ( 4.5A)	0.83A	2hyyC-2hckA: 30.4	2hyyC-2hckA: 30.72
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hk5	TYROSINE-PROTEIN KINASE HCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 259 ALA A 271 GLU A 288 VAL A 301 THR A 316 PHE A 318 ASP A 382	1BM A 499 ( 4.8A) 1BM A 499 (-3.6A) 1BM A 499 (-3.2A) None 1BM A 499 (-3.2A) 1BM A 499 (-4.1A) 1BM A 499 (-4.4A)	0.89A	2hyyC-2hk5A: 27.8	2hyyC-2hk5A: 47.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hk5	TYROSINE-PROTEIN KINASE HCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL A 259 ALA A 271 VAL A 301 THR A 316 PHE A 318 GLY A 322 LEU A 371 ALA A 381	1BM A 499 ( 4.8A) 1BM A 499 (-3.6A) None 1BM A 499 (-3.2A) 1BM A 499 (-4.1A) 1BM A 499 (-3.5A) 1BM A 499 (-4.4A) 1BM A 499 ( 3.7A)	0.72A	2hyyC-2hk5A: 27.8	2hyyC-2hk5A: 47.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hk5	TYROSINE-PROTEIN KINASE HCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL A 259 ALA A 271 VAL A 301 THR A 316 PHE A 318 LEU A 371 ALA A 381 ASP A 382	1BM A 499 ( 4.8A) 1BM A 499 (-3.6A) None 1BM A 499 (-3.2A) 1BM A 499 (-4.1A) 1BM A 499 (-4.4A) 1BM A 499 ( 3.7A) 1BM A 499 (-4.4A)	0.80A	2hyyC-2hk5A: 27.8	2hyyC-2hk5A: 47.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	10	ALA A 269 GLU A 286 ILE A 293 VAL A 299 THR A 315 PHE A 317 GLY A 321 LEU A 370 ALA A 380 ASP A 381	GIN A 600 (-3.1A) GIN A 600 (-3.6A) GIN A 600 (-4.5A) GIN A 600 (-4.6A) GIN A 600 (-3.4A) GIN A 600 (-4.3A) None GIN A 600 (-4.7A) GIN A 600 (-3.1A) GIN A 600 (-4.9A)	0.74A	2hyyC-2hz0A: 35.5	2hyyC-2hz0A: 100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	10	VAL A 256 ALA A 269 GLU A 286 ILE A 293 VAL A 299 THR A 315 PHE A 317 GLY A 321 LEU A 370 ALA A 380	GIN A 600 ( 4.7A) GIN A 600 (-3.1A) GIN A 600 (-3.6A) GIN A 600 (-4.5A) GIN A 600 (-4.6A) GIN A 600 (-3.4A) GIN A 600 (-4.3A) None GIN A 600 (-4.7A) GIN A 600 (-3.1A)	0.55A	2hyyC-2hz0A: 35.5	2hyyC-2hz0A: 100.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2jgz	CELL DIVISION PROTEIN KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 18 ALA A 31 GLU A 51 VAL A 64 PHE A 82 LEU A 134 ALA A 144	None	0.65A	2hyyC-2jgzA: 23.4	2hyyC-2jgzA: 27.44
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2og8	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	VAL A 259 ALA A 271 GLU A 288 VAL A 301 THR A 316 GLY A 322 LEU A 371 ALA A 381 ASP A 382	None 1N8 A 501 ( 3.4A) 1N8 A 501 ( 3.6A) None 1N8 A 501 ( 3.3A) 1N8 A 501 ( 3.5A) 1N8 A 501 ( 4.3A) 1N8 A 501 ( 3.3A) 1N8 A 501 ( 3.3A)	0.54A	2hyyC-2og8A: 32.6	2hyyC-2og8A: 47.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2ogv	MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL A 596 ALA A 614 GLU A 633 VAL A 647 THR A 663 GLY A 669 LEU A 785 ASP A 796	None	0.80A	2hyyC-2ogvA: 32.5	2hyyC-2ogvA: 37.34
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2p4i	ANGIOPOIETIN-1 RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 838 ALA A 853 GLY A 908 LEU A 971 ALA A 981 ASP A 982	MR9 A 301 (-4.6A) MR9 A 301 (-3.5A) MR9 A 301 ( 3.8A) MR9 A 301 (-4.5A) MR9 A 301 (-3.2A) MR9 A 301 (-4.2A)	0.45A	2hyyC-2p4iA: 23.9	2hyyC-2p4iA: 36.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2psq	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 495 ALA A 515 GLU A 534 ILE A 541 GLY A 570 LEU A 633 ALA A 643	None	0.65A	2hyyC-2psqA: 32.4	2hyyC-2psqA: 37.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2qlu	ACTIVIN RECEPTOR TYPE IIB (Homo sapiens)	PF00069 (Pkinase)	7	ALA A 215 ILE A 233 THR A 265 PHE A 267 GLY A 271 LEU A 328 ALA A 338	ADE A 488 (-3.2A) None ADE A 488 (-4.3A) ADE A 488 (-4.3A) ADE A 488 ( 4.1A) ADE A 488 (-4.4A) None	1.19A	2hyyC-2qluA: 24.9	2hyyC-2qluA: 24.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2qlu	ACTIVIN RECEPTOR TYPE IIB (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 204 ALA A 215 THR A 265 PHE A 267 GLY A 271 LEU A 328 ALA A 338	ADE A 488 ( 4.9A) ADE A 488 (-3.2A) ADE A 488 (-4.3A) ADE A 488 (-4.3A) ADE A 488 ( 4.1A) ADE A 488 (-4.4A) None	0.63A	2hyyC-2qluA: 24.9	2hyyC-2qluA: 24.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2v55	RHO-ASSOCIATED PROTEIN KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	7	ALA A 103 ILE A 127 VAL A 137 GLY A 158 LEU A 205 ALA A 215 ASP A 216	ANP A1480 ( 3.9A) None ANP A1480 (-4.7A) None ANP A1480 ( 4.7A) ANP A1480 ( 4.1A) ANP A1480 (-3.5A)	1.27A	2hyyC-2v55A: 17.8	2hyyC-2v55A: 22.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2v55	RHO-ASSOCIATED PROTEIN KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	7	ALA A 103 ILE A 127 VAL A 137 GLY A 159 LEU A 205 ALA A 215 ASP A 216	ANP A1480 ( 3.9A) None ANP A1480 (-4.7A) None ANP A1480 ( 4.7A) ANP A1480 ( 4.1A) ANP A1480 (-3.5A)	1.19A	2hyyC-2v55A: 17.8	2hyyC-2v55A: 22.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2v55	RHO-ASSOCIATED PROTEIN KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 90 ALA A 103 ILE A 127 VAL A 137 GLY A 159 LEU A 205 ALA A 215	None ANP A1480 ( 3.9A) None ANP A1480 (-4.7A) None ANP A1480 ( 4.7A) ANP A1480 ( 4.1A)	1.21A	2hyyC-2v55A: 17.8	2hyyC-2v55A: 22.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2wtk	STE20-RELATED KINASE ADAPTER PROTEIN ALPHA (Homo sapiens)	PF00069 (Pkinase)	7	VAL B 85 GLU B 118 VAL B 131 THR B 147 PHE B 149 GLY B 153 LEU B 202	ANP B 432 (-4.6A) None None ANP B 432 (-4.3A) ANP B 432 ( 4.9A) ANP B 432 ( 4.2A) ANP B 432 ( 4.7A)	0.80A	2hyyC-2wtkB: 22.5	2hyyC-2wtkB: 22.74
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2z7r	RIBOSOMAL PROTEIN S6 KINASE ALPHA-1 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 76 ALA A 92 VAL A 125 PHE A 143 GLY A 147 LEU A 194	None STU A 1 (-3.3A) None STU A 1 (-4.6A) STU A 1 ( 3.9A) STU A 1 (-4.6A)	0.43A	2hyyC-2z7rA: 21.9	2hyyC-2z7rA: 25.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2zv7	TYROSINE-PROTEIN KINASE LYN (Mus musculus)	PF07714 (Pkinase_Tyr)	7	VAL A 261 ALA A 273 GLU A 290 VAL A 303 THR A 319 PHE A 321 ASP A 385	None	0.93A	2hyyC-2zv7A: 26.3	2hyyC-2zv7A: 46.07
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2zv7	TYROSINE-PROTEIN KINASE LYN (Mus musculus)	PF07714 (Pkinase_Tyr)	7	VAL A 261 ALA A 273 VAL A 303 THR A 319 PHE A 321 ALA A 384 ASP A 385	None	0.75A	2hyyC-2zv7A: 26.3	2hyyC-2zv7A: 46.07
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2zv7	TYROSINE-PROTEIN KINASE LYN (Mus musculus)	PF07714 (Pkinase_Tyr)	8	VAL A 261 ALA A 273 VAL A 303 THR A 319 PHE A 321 GLY A 325 LEU A 374 ALA A 384	None	0.83A	2hyyC-2zv7A: 26.3	2hyyC-2zv7A: 46.07
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3c4f	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 492 ALA A 512 GLU A 531 ILE A 538 GLY A 567 LEU A 630 ALA A 640	None C4F A 1 (-3.3A) None None None C4F A 1 (-4.6A) C4F A 1 (-3.6A)	0.63A	2hyyC-3c4fA: 31.7	2hyyC-3c4fA: 40.98
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3d7u	TYROSINE-PROTEIN KINASE CSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 209 ALA A 220 GLU A 236 VAL A 249 THR A 266 GLY A 272 LEU A 321	None	0.66A	2hyyC-3d7uA: 27.3	2hyyC-3d7uA: 44.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3dko	EPHRIN TYPE-A RECEPTOR 7 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	7	VAL A 647 ALA A 663 VAL A 695 PHE A 713 GLY A 717 LEU A 765 ASP A 776	IHZ A1001 ( 4.4A) IHZ A1001 (-3.3A) IHZ A1001 ( 4.9A) None IHZ A1001 ( 3.9A) IHZ A1001 (-4.6A) IHZ A1001 (-4.8A)	0.74A	2hyyC-3dkoA: 31.5	2hyyC-3dkoA: 35.46
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3hng	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL A 841 ALA A 859 GLU A 878 ILE A 885 VAL A 892 GLY A 915 LEU A1029 ASP A1040	8ST A2001 ( 4.6A) 8ST A2001 ( 3.8A) 8ST A2001 (-3.7A) None 8ST A2001 ( 4.7A) None None None	0.87A	2hyyC-3hngA: 33.4	2hyyC-3hngA: 33.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3iec	SERINE/THREONINE-PRO TEIN KINASE MARK2 (Homo sapiens)	PF00069 (Pkinase) PF00627 (UBA)	7	VAL A 67 ALA A 80 VAL A 113 GLY A 135 LEU A 182 ALA A 192 ASP A 193	None	0.85A	2hyyC-3iecA: 22.7	2hyyC-3iecA: 26.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3llt	SERINE/THREONINE KINASE-1, PFLAMMER (Plasmodium falciparum)	PF00069 (Pkinase)	7	VAL A 566 ALA A 579 GLU A 596 ILE A 603 VAL A 614 GLY A 634 LEU A 684	ANP A 877 (-4.1A) ANP A 877 ( 3.7A) ANP A 877 ( 4.4A) None None None None	1.05A	2hyyC-3lltA: 21.4	2hyyC-3lltA: 22.69
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3mi9	CELL DIVISION PROTEIN KINASE 9 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 33 ALA A 46 GLU A 66 VAL A 79 PHE A 105 LEU A 156 ALA A 166	None	0.65A	2hyyC-3mi9A: 16.2	2hyyC-3mi9A: 25.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3my0	SERINE/THREONINE-PRO TEIN KINASE RECEPTOR R3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 216 ALA A 227 ILE A 245 THR A 277 GLY A 283 ALA A 347 ASP A 348	LDN A 600 (-4.5A) LDN A 600 (-3.2A) None LDN A 600 (-4.0A) LDN A 600 (-3.3A) LDN A 600 ( 3.8A) None	1.37A	2hyyC-3my0A: 25.2	2hyyC-3my0A: 28.12
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3my0	SERINE/THREONINE-PRO TEIN KINASE RECEPTOR R3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 216 ALA A 227 THR A 277 GLY A 283 LEU A 337 ALA A 347 ASP A 348	LDN A 600 (-4.5A) LDN A 600 (-3.2A) LDN A 600 (-4.0A) LDN A 600 (-3.3A) LDN A 600 (-4.6A) LDN A 600 ( 3.8A) None	0.85A	2hyyC-3my0A: 25.2	2hyyC-3my0A: 28.12
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3niz	RHODANESE FAMILY PROTEIN (Cryptosporidium parvum)	PF00069 (Pkinase)	7	VAL A 37 ALA A 49 GLU A 69 VAL A 82 PHE A 100 LEU A 151 ALA A 161	ADP A 314 (-4.0A) ADP A 314 (-3.5A) None None ADP A 314 ( 4.3A) ADP A 314 (-4.6A) None	0.77A	2hyyC-3nizA: 23.2	2hyyC-3nizA: 26.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3ppz	SERINE/THREONINE-PRO TEIN KINASE CTR1 (Arabidopsis thaliana)	PF07714 (Pkinase_Tyr)	6	ALA A 576 GLU A 596 VAL A 609 THR A 625 GLY A 631 LEU A 683	STU A 1 (-3.3A) None None STU A 1 (-4.1A) STU A 1 (-3.2A) STU A 1 (-4.3A)	0.51A	2hyyC-3ppzA: 29.2	2hyyC-3ppzA: 33.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3q4t	ACTIVIN RECEPTOR TYPE-2A (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 206 ALA A 217 THR A 267 PHE A 269 GLY A 273 LEU A 329 ALA A 339	TAK A 2 ( 4.9A) TAK A 2 (-3.5A) TAK A 2 (-3.5A) TAK A 2 (-4.3A) TAK A 2 (-3.6A) TAK A 2 (-4.6A) TAK A 2 ( 4.2A)	0.61A	2hyyC-3q4tA: 24.4	2hyyC-3q4tA: 24.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3q5i	PROTEIN KINASE (Plasmodium berghei)	PF00069 (Pkinase) PF13499 (EF-hand_7)	7	VAL A 71 ALA A 84 GLU A 115 THR A 144 PHE A 146 GLY A 150 LEU A 197	ANP A1634 (-4.1A) ANP A1634 (-3.6A) None ANP A1634 (-4.6A) ANP A1634 (-4.8A) None ANP A1634 (-4.4A)	0.70A	2hyyC-3q5iA: 20.3	2hyyC-3q5iA: 22.02
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3tt0	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 492 ALA A 512 GLU A 531 ILE A 538 GLY A 567 LEU A 630 ALA A 640	07J A 1 (-4.0A) 07J A 1 (-3.5A) 07J A 1 (-3.8A) None 07J A 1 (-3.7A) 07J A 1 ( 4.4A) 07J A 1 (-3.2A)	0.61A	2hyyC-3tt0A: 30.9	2hyyC-3tt0A: 40.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3txo	PROTEIN KINASE C ETA TYPE (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	7	ALA A 382 GLU A 403 PHE A 435 GLY A 439 LEU A 486 ALA A 496 ASP A 497	07U A 1 (-3.3A) 07U A 1 ( 4.8A) None None 07U A 1 (-4.3A) 07U A 1 ( 4.0A) 07U A 1 (-3.6A)	1.19A	2hyyC-3txoA: 18.2	2hyyC-3txoA: 24.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3txo	PROTEIN KINASE C ETA TYPE (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	7	ALA A 382 ILE A 406 PHE A 435 GLY A 439 LEU A 486 ALA A 496 ASP A 497	07U A 1 (-3.3A) None None None 07U A 1 (-4.3A) 07U A 1 ( 4.0A) 07U A 1 (-3.6A)	1.11A	2hyyC-3txoA: 18.2	2hyyC-3txoA: 24.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3txo	PROTEIN KINASE C ETA TYPE (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	7	VAL A 369 ALA A 382 GLU A 403 PHE A 435 GLY A 439 LEU A 486 ALA A 496	07U A 1 (-4.8A) 07U A 1 (-3.3A) 07U A 1 ( 4.8A) None None 07U A 1 (-4.3A) 07U A 1 ( 4.0A)	0.82A	2hyyC-3txoA: 18.2	2hyyC-3txoA: 24.65
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3txo	PROTEIN KINASE C ETA TYPE (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	7	VAL A 369 ALA A 382 ILE A 406 PHE A 435 GLY A 439 LEU A 486 ALA A 496	07U A 1 (-4.8A) 07U A 1 (-3.3A) None None None 07U A 1 (-4.3A) 07U A 1 ( 4.0A)	1.08A	2hyyC-3txoA: 18.2	2hyyC-3txoA: 24.65
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3vid	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	VAL A 848 ALA A 866 GLU A 885 ILE A 892 VAL A 899 PHE A 918 GLY A 922 LEU A1035 ASP A1046	4TT A2001 ( 4.5A) 4TT A2001 (-3.5A) None None None 4TT A2001 (-4.5A) 4TT A2001 (-3.7A) 4TT A2001 (-4.8A) None	0.72A	2hyyC-3vidA: 30.8	2hyyC-3vidA: 34.44
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3wzd	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL A 848 ALA A 866 GLU A 885 ILE A 892 VAL A 899 PHE A 918 GLY A 922 LEU A1035	LEV A1201 ( 4.9A) LEV A1201 (-3.5A) LEV A1201 (-3.7A) None None LEV A1201 (-4.7A) LEV A1201 (-3.6A) LEV A1201 (-4.8A)	0.64A	2hyyC-3wzdA: 31.9	2hyyC-3wzdA: 38.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3zdu	CYCLIN-DEPENDENT KINASE-LIKE 3 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 18 ALA A 31 GLU A 50 VAL A 63 PHE A 81 LEU A 132	38R A 350 ( 4.8A) 38R A 350 (-3.4A) 38R A 350 ( 4.8A) 38R A 350 ( 4.9A) 38R A 350 (-4.2A) 38R A 350 (-4.3A)	0.54A	2hyyC-3zduA: 22.6	2hyyC-3zduA: 26.57
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4agd	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	VAL A 848 ALA A 866 GLU A 885 ILE A 892 VAL A 899 PHE A 918 GLY A 922 LEU A1035 ASP A1046	None B49 A2000 (-3.5A) None None B49 A2000 ( 4.6A) B49 A2000 (-4.4A) B49 A2000 ( 3.7A) B49 A2000 (-4.5A) None	0.80A	2hyyC-4agdA: 33.0	2hyyC-4agdA: 35.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4aw5	EPHRIN TYPE-B RECEPTOR 4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 105 ALA A 121 THR A 169 PHE A 171 GLY A 175 LEU A 223	30K A1365 ( 4.6A) 30K A1365 (-3.2A) 30K A1365 (-3.8A) 30K A1365 (-4.4A) 30K A1365 (-3.5A) 30K A1365 (-4.5A)	0.51A	2hyyC-4aw5A: 27.1	2hyyC-4aw5A: 39.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4bbm	CYCLIN-DEPENDENT KINASE-LIKE 2 (Homo sapiens)	PF00069 (Pkinase)	6	TYR A 15 VAL A 18 ALA A 31 VAL A 64 PHE A 82 LEU A 133	TC0 A 500 (-4.0A) None TC0 A 500 (-3.5A) TC0 A 500 (-4.7A) TC0 A 500 (-4.2A) TC0 A 500 (-4.3A)	0.53A	2hyyC-4bbmA: 22.2	2hyyC-4bbmA: 29.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4bc6	SERINE/THREONINE-PRO TEIN KINASE 10 (Homo sapiens)	PF00069 (Pkinase)	8	VAL A 50 ALA A 63 GLU A 81 VAL A 94 PHE A 112 GLY A 116 LEU A 164 ALA A 174	XZN A1317 ( 4.7A) XZN A1317 (-3.5A) XZN A1317 (-3.9A) XZN A1317 (-4.4A) XZN A1317 (-4.5A) XZN A1317 ( 3.7A) XZN A1317 (-4.7A) XZN A1317 ( 4.3A)	0.61A	2hyyC-4bc6A: 22.1	2hyyC-4bc6A: 29.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4bc6	SERINE/THREONINE-PRO TEIN KINASE 10 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 50 ALA A 63 ILE A 84 PHE A 112 GLY A 116 LEU A 164 ALA A 174	XZN A1317 ( 4.7A) XZN A1317 (-3.5A) None XZN A1317 (-4.5A) XZN A1317 ( 3.7A) XZN A1317 (-4.7A) XZN A1317 ( 4.3A)	1.01A	2hyyC-4bc6A: 22.1	2hyyC-4bc6A: 29.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ckr	EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL A 624 ALA A 653 GLU A 672 THR A 701 GLY A 707 LEU A 773 ALA A 783 ASP A 784	DI1 A1000 (-4.8A) DI1 A1000 (-3.6A) DI1 A1000 (-3.8A) DI1 A1000 (-3.6A) None DI1 A1000 (-4.5A) DI1 A1000 (-3.7A) DI1 A1000 (-4.1A)	0.57A	2hyyC-4ckrA: 32.2	2hyyC-4ckrA: 37.74
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4crs	SERINE/THREONINE-PRO TEIN KINASE N2 (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	7	VAL A 671 ALA A 684 GLU A 705 VAL A 721 GLY A 743 LEU A 789 ALA A 799	AGS A1985 (-4.6A) AGS A1985 (-3.5A) None None None AGS A1985 (-4.8A) AGS A1985 ( 4.5A)	0.61A	2hyyC-4crsA: 21.0	2hyyC-4crsA: 26.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4crs	SERINE/THREONINE-PRO TEIN KINASE N2 (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	7	VAL A 671 ALA A 684 ILE A 708 VAL A 721 GLY A 743 LEU A 789 ALA A 799	AGS A1985 (-4.6A) AGS A1985 (-3.5A) None None None AGS A1985 (-4.8A) AGS A1985 ( 4.5A)	1.01A	2hyyC-4crsA: 21.0	2hyyC-4crsA: 26.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4f0g	SERINE/THREONINE-PRO TEIN KINASE ROCO4 (Dictyostelium discoideum)	PF07714 (Pkinase_Tyr)	7	VAL A1040 ALA A1053 GLU A1078 VAL A1091 PHE A1107 GLY A1111 ALA A1176	None	0.83A	2hyyC-4f0gA: 26.8	2hyyC-4f0gA: 30.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4fie	SERINE/THREONINE-PRO TEIN KINASE PAK 4 (Homo sapiens)	PF00069 (Pkinase) PF00786 (PBD)	7	VAL A 335 ALA A 348 GLU A 366 VAL A 379 PHE A 397 GLY A 401 LEU A 447	ANP A1001 (-4.7A) ANP A1001 (-3.6A) ANP A1001 (-3.6A) None ANP A1001 ( 4.6A) None ANP A1001 (-4.7A)	0.80A	2hyyC-4fieA: 22.3	2hyyC-4fieA: 18.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4hvi	TYROSINE-PROTEIN KINASE JAK3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 836 ALA A 853 GLU A 871 VAL A 884 GLY A 908 LEU A 956 ALA A 966	19S A1201 (-4.4A) 19S A1201 (-3.3A) None None 19S A1201 ( 3.8A) 19S A1201 (-4.5A) 19S A1201 ( 4.1A)	0.55A	2hyyC-4hviA: 30.3	2hyyC-4hviA: 34.69
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4k33	FIBROBLAST GROWTH FACTOR RECEPTOR 3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 486 ALA A 506 GLU A 525 ILE A 532 GLY A 561 LEU A 624 ALA A 634	ACP A 801 (-4.2A) ACP A 801 (-3.3A) ACP A 801 ( 4.8A) None ACP A 801 ( 4.6A) ACP A 801 (-4.4A) None	0.81A	2hyyC-4k33A: 26.4	2hyyC-4k33A: 39.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4lg4	SERINE/THREONINE-PRO TEIN KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 41 ALA A 54 GLU A 70 VAL A 83 GLY A 105 LEU A 153 ALA A 163	GOL A 404 (-4.5A) GOL A 404 ( 3.1A) None GOL A 403 (-4.1A) GOL A 404 (-3.6A) GOL A 403 ( 4.4A) GOL A 403 ( 3.0A)	1.09A	2hyyC-4lg4A: 17.7	2hyyC-4lg4A: 24.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4o27	SERINE/THREONINE-PRO TEIN KINASE 24 (Homo sapiens)	PF00069 (Pkinase)	7	VAL B 38 ALA B 51 GLU B 70 GLY B 105 LEU B 151 ALA B 161 ASP B 162	ADP B 500 (-4.5A) ADP B 500 (-3.3A) None None ADP B 500 (-4.7A) None ADP B 500 ( 3.4A)	0.89A	2hyyC-4o27B: 18.4	2hyyC-4o27B: 29.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4o38	CYCLIN-G-ASSOCIATED KINASE (Homo sapiens)	PF00069 (Pkinase)	7	ALA A 67 GLU A 85 VAL A 99 THR A 123 GLY A 128 LEU A 180 ASP A 191	SIN A 401 ( 3.7A) None None None SIN A 401 (-3.5A) SIN A 401 ( 4.5A) None	0.95A	2hyyC-4o38A: 19.7	2hyyC-4o38A: 24.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4o38	CYCLIN-G-ASSOCIATED KINASE (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 54 ALA A 67 GLU A 85 VAL A 99 THR A 123 GLY A 128 LEU A 180	None SIN A 401 ( 3.7A) None None None SIN A 401 (-3.5A) SIN A 401 ( 4.5A)	0.63A	2hyyC-4o38A: 19.7	2hyyC-4o38A: 24.56
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4rt7	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 624 ALA A 642 GLU A 661 VAL A 675 GLY A 697 LEU A 818 ASP A 829	None P30 A1001 (-3.4A) P30 A1001 (-3.6A) None P30 A1001 (-3.4A) P30 A1001 (-4.6A) None	0.63A	2hyyC-4rt7A: 29.0	2hyyC-4rt7A: 33.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ueu	TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL (synthetic construct)	PF07714 (Pkinase_Tyr)	7	VAL A 22 ALA A 35 ILE A 55 THR A 81 GLY A 87 LEU A 136 ALA A 146	ACP A1264 (-4.7A) ACP A1264 (-2.9A) None ACP A1264 (-4.5A) ACP A1264 (-3.5A) ACP A1264 ( 4.8A) None	1.23A	2hyyC-4ueuA: 33.2	2hyyC-4ueuA: 66.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ueu	TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL (synthetic construct)	PF07714 (Pkinase_Tyr)	7	VAL A 22 ALA A 35 ILE A 55 THR A 81 LEU A 136 ALA A 146 ASP A 147	ACP A1264 (-4.7A) ACP A1264 (-2.9A) None ACP A1264 (-4.5A) ACP A1264 ( 4.8A) None None	1.18A	2hyyC-4ueuA: 33.2	2hyyC-4ueuA: 66.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ueu	TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL (synthetic construct)	PF07714 (Pkinase_Tyr)	7	VAL A 22 ALA A 35 VAL A 65 THR A 81 GLY A 87 LEU A 136 ALA A 146	ACP A1264 (-4.7A) ACP A1264 (-2.9A) None ACP A1264 (-4.5A) ACP A1264 (-3.5A) ACP A1264 ( 4.8A) None	0.58A	2hyyC-4ueuA: 33.2	2hyyC-4ueuA: 66.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ueu	TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL (synthetic construct)	PF07714 (Pkinase_Tyr)	7	VAL A 22 ALA A 35 VAL A 65 THR A 81 LEU A 136 ALA A 146 ASP A 147	ACP A1264 (-4.7A) ACP A1264 (-2.9A) None ACP A1264 (-4.5A) ACP A1264 ( 4.8A) None None	0.76A	2hyyC-4ueuA: 33.2	2hyyC-4ueuA: 66.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	PF00069 (Pkinase)	8	VAL A 48 ALA A 61 VAL A 92 PHE A 110 GLY A 114 LEU A 162 ALA A 172 ASP A 173	None 6UI A 700 (-3.3A) None 6UI A 700 (-4.3A) 6UI A 700 ( 4.2A) 6UI A 700 (-4.2A) 6UI A 700 ( 4.1A) None	0.97A	2hyyC-4usfA: 25.0	2hyyC-4usfA: 28.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4wsq	AP2-ASSOCIATED PROTEIN KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	7	ALA A 72 GLU A 90 VAL A 104 PHE A 128 GLY A 132 LEU A 183 ASP A 194	KSA A 405 (-3.2A) None None KSA A 405 (-4.8A) KSA A 405 (-3.5A) KSA A 405 (-4.6A) ZN A 403 ( 2.6A)	0.96A	2hyyC-4wsqA: 23.0	2hyyC-4wsqA: 23.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4wsq	AP2-ASSOCIATED PROTEIN KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 60 ALA A 72 GLU A 90 VAL A 104 PHE A 128 GLY A 132 LEU A 183	KSA A 405 ( 4.9A) KSA A 405 (-3.2A) None None KSA A 405 (-4.8A) KSA A 405 (-3.5A) KSA A 405 (-4.6A)	0.62A	2hyyC-4wsqA: 23.0	2hyyC-4wsqA: 23.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4xbr	PROTEIN FAM212A,SERINE/THREO NINE-PROTEIN KINASE PAK 4 (Homo sapiens)	PF00069 (Pkinase) PF15342 (FAM212)	7	VAL A 335 ALA A 348 GLU A 366 VAL A 379 PHE A 397 GLY A 401 LEU A 447	ATP A 601 (-4.4A) ATP A 601 ( 3.7A) ATP A 601 ( 3.7A) None ATP A 601 (-4.6A) None None	0.81A	2hyyC-4xbrA: 16.6	2hyyC-4xbrA: 21.58
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xcu	FIBROBLAST GROWTH FACTOR RECEPTOR 4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 481 ALA A 501 GLU A 520 ILE A 527 GLY A 556 LEU A 619 ALA A 629	40M A1002 ( 4.5A) 40M A1002 ( 4.1A) 40M A1002 (-3.7A) None 40M A1002 ( 3.7A) 40M A1002 (-4.5A) 40M A1002 (-3.0A)	0.74A	2hyyC-4xcuA: 31.4	2hyyC-4xcuA: 40.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	no annotation	9	VAL B 275 ALA B 288 ILE B 312 VAL B 318 THR B 334 PHE B 336 GLY B 340 LEU B 389 ALA B 399	1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) None 1N1 B 601 ( 4.3A) 1N1 B 601 (-3.3A) 1N1 B 601 ( 4.2A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.69A	2hyyC-4xeyB: 36.1	2hyyC-4xeyB: 100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xuf	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 624 ALA A 642 GLU A 661 VAL A 675 GLY A 697 LEU A 818 ASP A 829	P30 A1001 ( 4.8A) P30 A1001 (-3.5A) P30 A1001 (-3.1A) None P30 A1001 (-3.5A) P30 A1001 (-4.3A) None	0.51A	2hyyC-4xufA: 33.9	2hyyC-4xufA: 38.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4yff	SERINE/THREONINE-PRO TEIN KINASE TNNI3K (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 477 ALA A 488 GLU A 509 THR A 539 GLY A 545 LEU A 595 ALA A 605	None 4CV A 801 (-3.5A) None 4CV A 801 (-2.8A) 4CV A 801 ( 4.0A) 4CV A 801 (-4.4A) 4CV A 801 ( 3.9A)	0.65A	2hyyC-4yffA: 25.5	2hyyC-4yffA: 29.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5a46	FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 492 ALA A 512 GLU A 531 ILE A 538 GLY A 567 LEU A 630 ALA A 640	38O A1769 (-4.5A) 38O A1769 (-3.6A) EDO A1766 (-4.1A) None 38O A1769 (-3.4A) 38O A1769 (-4.6A) EDO A1766 ( 4.4A)	0.72A	2hyyC-5a46A: 30.6	2hyyC-5a46A: 40.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ci7	SERINE/THREONINE-PRO TEIN KINASE ULK1 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 30 ALA A 44 VAL A 76 GLY A 98 LEU A 145 ALA A 164	51W A 401 ( 4.3A) 51W A 401 (-3.4A) None 51W A 401 (-3.7A) 51W A 401 (-4.5A) None	0.50A	2hyyC-5ci7A: 23.2	2hyyC-5ci7A: 28.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5e8y	TGF-BETA RECEPTOR TYPE-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 258 ALA A 275 GLU A 290 THR A 325 PHE A 327 GLY A 331 LEU A 386	STU A 601 (-4.0A) STU A 601 (-3.1A) STU A 601 ( 3.8A) STU A 601 ( 3.7A) STU A 601 (-3.4A) STU A 601 (-3.5A) STU A 601 (-3.9A)	0.72A	2hyyC-5e8yA: 19.0	2hyyC-5e8yA: 27.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5es1	MAP/MICROTUBULE AFFINITY-REGULATING KINASE 4 (Homo sapiens)	PF00069 (Pkinase) PF00627 (UBA)	7	VAL A 70 ALA A 83 GLU A 103 VAL A 116 GLY A 138 LEU A 185 ALA A 195	5RC A4000 (-4.6A) 5RC A4000 (-3.6A) None None 5RC A4000 (-3.3A) None 5RC A4000 ( 3.9A)	0.94A	2hyyC-5es1A: 11.0	2hyyC-5es1A: 25.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5eyk	AURORA KINASE B-A (Xenopus laevis)	PF00069 (Pkinase)	7	VAL A 107 ALA A 120 PHE A 172 GLY A 176 LEU A 223 ALA A 233 ASP A 234	5U5 A 401 ( 4.3A) 5U5 A 401 (-3.5A) 5U5 A 401 (-4.5A) 5U5 A 401 (-3.4A) 5U5 A 401 (-4.7A) None None	0.81A	2hyyC-5eykA: 17.7	2hyyC-5eykA: 25.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5grn	PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	VAL A 607 ALA A 625 GLU A 644 VAL A 658 THR A 674 GLY A 680 LEU A 825 ASP A 836	748 A1001 ( 4.7A) 748 A1001 (-3.7A) 748 A1001 (-3.3A) 748 A1001 ( 4.8A) 748 A1001 (-3.2A) 748 A1001 ( 4.0A) 748 A1001 (-4.3A) 748 A1001 (-4.8A)	0.61A	2hyyC-5grnA: 29.6	2hyyC-5grnA: 36.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5gz8	PROTEIN O-MANNOSE KINASE (Mus musculus)	PF07714 (Pkinase_Tyr)	6	VAL A 94 ALA A 105 VAL A 134 THR A 148 GLY A 154 LEU A 215	None	0.34A	2hyyC-5gz8A: 19.4	2hyyC-5gz8A: 23.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5hu3	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE TYPE II ALPHA CHAIN (Drosophila melanogaster)	PF00069 (Pkinase)	7	VAL A 28 ALA A 41 GLU A 61 VAL A 74 GLY A 96 LEU A 143 ALA A 156	ADP A 301 (-3.7A) ADP A 301 (-3.5A) None None None ADP A 301 (-4.7A) ADP A 301 ( 4.8A)	0.60A	2hyyC-5hu3A: 23.4	2hyyC-5hu3A: 26.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5j5t	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	8	VAL A 30 ALA A 43 GLU A 61 VAL A 74 PHE A 92 GLY A 96 LEU A 143 ALA A 153	6G2 A 901 ( 4.9A) 6G2 A 901 (-3.2A) None None 6G2 A 901 (-4.1A) 6G2 A 901 (-3.6A) 6G2 A 901 (-4.7A) 6G2 A 901 ( 4.2A)	0.59A	2hyyC-5j5tA: 21.9	2hyyC-5j5tA: 24.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5lpy	PROTEIN BRASSINOSTEROID INSENSITIVE 1 (Arabidopsis thaliana)	PF00069 (Pkinase)	7	VAL A 897 ALA A 909 GLU A 927 VAL A 940 PHE A 958 GLY A 962 LEU A1016	ATP A1200 ( 4.5A) ATP A1200 (-3.5A) None None ATP A1200 ( 4.0A) ATP A1200 ( 4.0A) ATP A1200 (-4.6A)	0.63A	2hyyC-5lpyA: 23.2	2hyyC-5lpyA: 30.49
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5lpz	PROTEIN BRASSINOSTEROID INSENSITIVE 1 (Arabidopsis thaliana)	PF00069 (Pkinase)	7	VAL A 897 ALA A 909 GLU A 927 VAL A 940 PHE A 958 GLY A 962 LEU A1016	ADP A1200 (-4.4A) ADP A1200 (-3.5A) None None ADP A1200 (-4.1A) ADP A1200 ( 4.0A) ADP A1200 (-4.7A)	0.69A	2hyyC-5lpzA: 23.2	2hyyC-5lpzA: 29.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5u7q	RHO-ASSOCIATED PROTEIN KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	7	ALA A 119 ILE A 143 VAL A 153 GLY A 174 LEU A 221 ALA A 231 ASP A 232	None	1.20A	2hyyC-5u7qA: 18.6	2hyyC-5u7qA: 23.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5u7q	RHO-ASSOCIATED PROTEIN KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	7	ALA A 119 ILE A 143 VAL A 153 GLY A 175 LEU A 221 ALA A 231 ASP A 232	None	1.09A	2hyyC-5u7qA: 18.6	2hyyC-5u7qA: 23.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5u7q	RHO-ASSOCIATED PROTEIN KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 106 ALA A 119 GLU A 140 VAL A 153 GLY A 175 LEU A 221 ALA A 231	None	0.93A	2hyyC-5u7qA: 18.6	2hyyC-5u7qA: 23.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5u7q	RHO-ASSOCIATED PROTEIN KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 106 ALA A 119 ILE A 143 VAL A 153 GLY A 175 LEU A 221 ALA A 231	None	1.00A	2hyyC-5u7qA: 18.6	2hyyC-5u7qA: 23.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5vef	SERINE/THREONINE-PRO TEIN KINASE PAK 4 (Homo sapiens)	no annotation	7	VAL A 335 ALA A 348 GLU A 366 VAL A 379 PHE A 397 GLY A 401 LEU A 447	M77 A 601 (-4.5A) M77 A 601 ( 3.5A) None None M77 A 601 (-4.1A) M77 A 601 ( 4.8A) M77 A 601 (-4.6A)	0.77A	2hyyC-5vefA: 22.8	2hyyC-5vefA: 21.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5vil	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 5 (Homo sapiens)	no annotation	6	VAL A 694 ALA A 707 GLU A 725 VAL A 738 GLY A 760 LEU A 810	9E1 A1001 ( 4.0A) 9E1 A1001 (-3.5A) None 9E1 A1001 (-4.1A) 9E1 A1001 (-3.4A) 9E1 A1001 (-4.5A)	0.53A	2hyyC-5vilA: 19.3	2hyyC-5vilA: 15.30

[["2HYY_C_STIC600_1","1h4l","Homo sapiens","CELL DIVISION PROTEIN KINASE 5","PF00069(Pkinase)",7,"VAL A  18;ALA A  31;GLU A  51;VAL A  64;PHE A  82;LEU A 133;ALA A 143","None","0.76A","2hyyC-1h4lA:23.8","2hyyC-1h4lA:25.96"],["2HYY_C_STIC600_1","1k9a","Rattus norvegicus","CARBOXYL-TERMINAL SRC KINASE","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",7,"VAL A 209;ALA A 220;GLU A 236;VAL A 249;THR A 266;GLY A 272;LEU A 321","None","0.66A","2hyyC-1k9aA:31.3","2hyyC-1k9aA:30.63"],["2HYY_C_STIC600_1","1luf","Rattus norvegicus","MUSCLE-SPECIFIC TYROSINE KINASE RECEPTOR MUSK","PF07714(Pkinase_Tyr)",7,"VAL A 588;ALA A 606;VAL A 638;GLY A 660;LEU A 731;ALA A 741;ASP A 742","None","0.76A","2hyyC-1lufA:30.2","2hyyC-1lufA:37.65"],["2HYY_C_STIC600_1","1opk","Mus musculus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",11,"TYR A 272;VAL A 275;ALA A 288;GLU A 305;ILE A 312;VAL A 318;THR A 334;PHE A 336;GLY A 340;LEU A 389;ALA A 399","P16 A   2 (-3.6A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.2A);None;P16 A   2 ( 4.7A);P16 A   2 (-3.7A);P16 A   2 ( 4.4A);P16 A   2 (-3.4A);P16 A   2 (-4.4A);P16 A   2 (-3.5A)","0.84A","2hyyC-1opkA:35.2","2hyyC-1opkA:99.27"],["2HYY_C_STIC600_1","1t46","Homo sapiens","HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG","PF07714(Pkinase_Tyr)",8,"VAL A 603;ALA A 621;GLU A 640;VAL A 654;THR A 670;GLY A 676;LEU A 799;ASP A 810","STI A   3 ( 4.6A);STI A   3 (-3.5A);STI A   3 (-3.6A);STI A   3 (-4.3A);STI A   3 (-3.2A);STI A   3 ( 3.8A);STI A   3 (-4.4A);STI A   3 (-3.9A)","0.55A","2hyyC-1t46A:29.4","2hyyC-1t46A:37.22"],["2HYY_C_STIC600_1","1u59","Homo sapiens","TYROSINE-PROTEIN KINASE ZAP-70","PF07714(Pkinase_Tyr)",6,"VAL A 352;ALA A 367;GLU A 386;VAL A 399;GLY A 420;LEU A 468","STU A 100 (-4.8A);STU A 100 (-3.2A);None;None;STU A 100 (-3.5A);STU A 100 (-4.5A)","0.45A","2hyyC-1u59A:31.0","2hyyC-1u59A:38.19"],["2HYY_C_STIC600_1","2buj","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 16","PF00069(Pkinase)",7,"VAL A  34;ALA A  47;GLU A  65;PHE A 100;GLY A 104;LEU A 155;ASP A 166","STU A1301 (-4.8A);STU A1301 (-3.6A);None;STU A1301 (-4.5A);STU A1301 ( 4.0A);STU A1301 ( 4.8A);None","0.84A","2hyyC-2bujA:23.2","2hyyC-2bujA:23.58"],["2HYY_C_STIC600_1","2dq7","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN","PF07714(Pkinase_Tyr)",8,"VAL X  25;ALA X  37;GLU X  54;VAL X  67;THR X  82;GLY X  88;LEU X 137;ALA X 147","STU X 902 ( 4.8A);STU X 902 (-3.1A);STU X 902 ( 4.4A);None;STU X 902 (-4.1A);STU X 902 (-3.5A);STU X 902 (-4.4A);STU X 902 ( 4.1A)","0.65A","2hyyC-2dq7X:32.6","2hyyC-2dq7X:46.10"],["2HYY_C_STIC600_1","2eu9","Homo sapiens","DUAL SPECIFICITY PROTEIN KINASE CLK3","PF00069(Pkinase)",7,"VAL A 170;ALA A 184;GLU A 201;ILE A 208;VAL A 220;LEU A 290;ALA A 319","None","0.73A","2hyyC-2eu9A:22.0","2hyyC-2eu9A:24.66"],["2HYY_C_STIC600_1","2eu9","Homo sapiens","DUAL SPECIFICITY PROTEIN KINASE CLK3","PF00069(Pkinase)",7,"VAL A 170;ALA A 184;GLU A 201;VAL A 220;GLY A 240;LEU A 290;ALA A 319","None","1.04A","2hyyC-2eu9A:22.0","2hyyC-2eu9A:24.66"],["2HYY_C_STIC600_1","2h8h","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",7,"VAL A 281;ALA A 293;VAL A 323;THR A 338;GLY A 344;LEU A 393;ALA A 403","H8H A 534 (-4.4A);H8H A 534 (-3.2A);None;H8H A 534 (-3.1A);H8H A 534 (-3.3A);H8H A 534 (-4.5A);H8H A 534 ( 4.0A)","0.81A","2hyyC-2h8hA:31.0","2hyyC-2h8hA:27.56"],["2HYY_C_STIC600_1","2hck","Homo sapiens","HEMATOPOETIC CELL KINASE HCK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",7,"ALA A 293;VAL A 323;THR A 338;PHE A 340;GLY A 344;LEU A 393;ALA A 403","QUE A   1 (-3.5A);None;QUE A   1 (-3.3A);QUE A   1 (-4.2A);QUE A   1 (-3.0A);QUE A   1 (-4.4A);QUE A   1 ( 4.5A)","0.63A","2hyyC-2hckA:30.4","2hyyC-2hckA:30.72"],["2HYY_C_STIC600_1","2hck","Homo sapiens","HEMATOPOETIC CELL KINASE HCK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",7,"VAL A 281;ALA A 293;VAL A 323;THR A 338;PHE A 340;LEU A 393;ALA A 403","QUE A   1 ( 4.8A);QUE A   1 (-3.5A);None;QUE A   1 (-3.3A);QUE A   1 (-4.2A);QUE A   1 (-4.4A);QUE A   1 ( 4.5A)","0.83A","2hyyC-2hckA:30.4","2hyyC-2hckA:30.72"],["2HYY_C_STIC600_1","2hk5","Homo sapiens","TYROSINE-PROTEIN KINASE HCK","PF07714(Pkinase_Tyr)",7,"VAL A 259;ALA A 271;GLU A 288;VAL A 301;THR A 316;PHE A 318;ASP A 382","1BM A 499 ( 4.8A);1BM A 499 (-3.6A);1BM A 499 (-3.2A);None;1BM A 499 (-3.2A);1BM A 499 (-4.1A);1BM A 499 (-4.4A)","0.89A","2hyyC-2hk5A:27.8","2hyyC-2hk5A:47.81"],["2HYY_C_STIC600_1","2hk5","Homo sapiens","TYROSINE-PROTEIN KINASE HCK","PF07714(Pkinase_Tyr)",8,"VAL A 259;ALA A 271;VAL A 301;THR A 316;PHE A 318;GLY A 322;LEU A 371;ALA A 381","1BM A 499 ( 4.8A);1BM A 499 (-3.6A);None;1BM A 499 (-3.2A);1BM A 499 (-4.1A);1BM A 499 (-3.5A);1BM A 499 (-4.4A);1BM A 499 ( 3.7A)","0.72A","2hyyC-2hk5A:27.8","2hyyC-2hk5A:47.81"],["2HYY_C_STIC600_1","2hk5","Homo sapiens","TYROSINE-PROTEIN KINASE HCK","PF07714(Pkinase_Tyr)",8,"VAL A 259;ALA A 271;VAL A 301;THR A 316;PHE A 318;LEU A 371;ALA A 381;ASP A 382","1BM A 499 ( 4.8A);1BM A 499 (-3.6A);None;1BM A 499 (-3.2A);1BM A 499 (-4.1A);1BM A 499 (-4.4A);1BM A 499 ( 3.7A);1BM A 499 (-4.4A)","0.80A","2hyyC-2hk5A:27.8","2hyyC-2hk5A:47.81"],["2HYY_C_STIC600_1","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",10,"ALA A 269;GLU A 286;ILE A 293;VAL A 299;THR A 315;PHE A 317;GLY A 321;LEU A 370;ALA A 380;ASP A 381","GIN A 600 (-3.1A);GIN A 600 (-3.6A);GIN A 600 (-4.5A);GIN A 600 (-4.6A);GIN A 600 (-3.4A);GIN A 600 (-4.3A);None;GIN A 600 (-4.7A);GIN A 600 (-3.1A);GIN A 600 (-4.9A)","0.74A","2hyyC-2hz0A:35.5","2hyyC-2hz0A:100.00"],["2HYY_C_STIC600_1","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",10,"VAL A 256;ALA A 269;GLU A 286;ILE A 293;VAL A 299;THR A 315;PHE A 317;GLY A 321;LEU A 370;ALA A 380","GIN A 600 ( 4.7A);GIN A 600 (-3.1A);GIN A 600 (-3.6A);GIN A 600 (-4.5A);GIN A 600 (-4.6A);GIN A 600 (-3.4A);GIN A 600 (-4.3A);None;GIN A 600 (-4.7A);GIN A 600 (-3.1A)","0.55A","2hyyC-2hz0A:35.5","2hyyC-2hz0A:100.00"],["2HYY_C_STIC600_1","2jgz","Homo sapiens","CELL DIVISION PROTEIN KINASE 2","PF00069(Pkinase)",7,"VAL A  18;ALA A  31;GLU A  51;VAL A  64;PHE A  82;LEU A 134;ALA A 144","None","0.65A","2hyyC-2jgzA:23.4","2hyyC-2jgzA:27.44"],["2HYY_C_STIC600_1","2og8","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK","PF07714(Pkinase_Tyr)",9,"VAL A 259;ALA A 271;GLU A 288;VAL A 301;THR A 316;GLY A 322;LEU A 371;ALA A 381;ASP A 382","None;1N8 A 501 ( 3.4A);1N8 A 501 ( 3.6A);None;1N8 A 501 ( 3.3A);1N8 A 501 ( 3.5A);1N8 A 501 ( 4.3A);1N8 A 501 ( 3.3A);1N8 A 501 ( 3.3A)","0.54A","2hyyC-2og8A:32.6","2hyyC-2og8A:47.97"],["2HYY_C_STIC600_1","2ogv","Homo sapiens","MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR","PF07714(Pkinase_Tyr)",8,"VAL A 596;ALA A 614;GLU A 633;VAL A 647;THR A 663;GLY A 669;LEU A 785;ASP A 796","None","0.80A","2hyyC-2ogvA:32.5","2hyyC-2ogvA:37.34"],["2HYY_C_STIC600_1","2p4i","Homo sapiens","ANGIOPOIETIN-1 RECEPTOR","PF07714(Pkinase_Tyr)",6,"VAL A 838;ALA A 853;GLY A 908;LEU A 971;ALA A 981;ASP A 982","MR9 A 301 (-4.6A);MR9 A 301 (-3.5A);MR9 A 301 ( 3.8A);MR9 A 301 (-4.5A);MR9 A 301 (-3.2A);MR9 A 301 (-4.2A)","0.45A","2hyyC-2p4iA:23.9","2hyyC-2p4iA:36.83"],["2HYY_C_STIC600_1","2psq","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"VAL A 495;ALA A 515;GLU A 534;ILE A 541;GLY A 570;LEU A 633;ALA A 643","None","0.65A","2hyyC-2psqA:32.4","2hyyC-2psqA:37.46"],["2HYY_C_STIC600_1","2qlu","Homo sapiens","ACTIVIN RECEPTOR TYPE IIB","PF00069(Pkinase)",7,"ALA A 215;ILE A 233;THR A 265;PHE A 267;GLY A 271;LEU A 328;ALA A 338","ADE A 488 (-3.2A);None;ADE A 488 (-4.3A);ADE A 488 (-4.3A);ADE A 488 ( 4.1A);ADE A 488 (-4.4A);None","1.19A","2hyyC-2qluA:24.9","2hyyC-2qluA:24.38"],["2HYY_C_STIC600_1","2qlu","Homo sapiens","ACTIVIN RECEPTOR TYPE IIB","PF00069(Pkinase)",7,"VAL A 204;ALA A 215;THR A 265;PHE A 267;GLY A 271;LEU A 328;ALA A 338","ADE A 488 ( 4.9A);ADE A 488 (-3.2A);ADE A 488 (-4.3A);ADE A 488 (-4.3A);ADE A 488 ( 4.1A);ADE A 488 (-4.4A);None","0.63A","2hyyC-2qluA:24.9","2hyyC-2qluA:24.38"],["2HYY_C_STIC600_1","2v55","Homo sapiens","RHO-ASSOCIATED PROTEIN KINASE 1","PF00069(Pkinase)",7,"ALA A 103;ILE A 127;VAL A 137;GLY A 158;LEU A 205;ALA A 215;ASP A 216","ANP A1480 ( 3.9A);None;ANP A1480 (-4.7A);None;ANP A1480 ( 4.7A);ANP A1480 ( 4.1A);ANP A1480 (-3.5A)","1.27A","2hyyC-2v55A:17.8","2hyyC-2v55A:22.68"],["2HYY_C_STIC600_1","2v55","Homo sapiens","RHO-ASSOCIATED PROTEIN KINASE 1","PF00069(Pkinase)",7,"ALA A 103;ILE A 127;VAL A 137;GLY A 159;LEU A 205;ALA A 215;ASP A 216","ANP A1480 ( 3.9A);None;ANP A1480 (-4.7A);None;ANP A1480 ( 4.7A);ANP A1480 ( 4.1A);ANP A1480 (-3.5A)","1.19A","2hyyC-2v55A:17.8","2hyyC-2v55A:22.68"],["2HYY_C_STIC600_1","2v55","Homo sapiens","RHO-ASSOCIATED PROTEIN KINASE 1","PF00069(Pkinase)",7,"VAL A  90;ALA A 103;ILE A 127;VAL A 137;GLY A 159;LEU A 205;ALA A 215","None;ANP A1480 ( 3.9A);None;ANP A1480 (-4.7A);None;ANP A1480 ( 4.7A);ANP A1480 ( 4.1A)","1.21A","2hyyC-2v55A:17.8","2hyyC-2v55A:22.68"],["2HYY_C_STIC600_1","2wtk","Homo sapiens","STE20-RELATED KINASE ADAPTER PROTEIN ALPHA","PF00069(Pkinase)",7,"VAL B  85;GLU B 118;VAL B 131;THR B 147;PHE B 149;GLY B 153;LEU B 202","ANP B 432 (-4.6A);None;None;ANP B 432 (-4.3A);ANP B 432 ( 4.9A);ANP B 432 ( 4.2A);ANP B 432 ( 4.7A)","0.80A","2hyyC-2wtkB:22.5","2hyyC-2wtkB:22.74"],["2HYY_C_STIC600_1","2z7r","Homo sapiens","RIBOSOMAL PROTEIN S6 KINASE ALPHA-1","PF00069(Pkinase)",6,"VAL A  76;ALA A  92;VAL A 125;PHE A 143;GLY A 147;LEU A 194","None;STU A   1 (-3.3A);None;STU A   1 (-4.6A);STU A   1 ( 3.9A);STU A   1 (-4.6A)","0.43A","2hyyC-2z7rA:21.9","2hyyC-2z7rA:25.00"],["2HYY_C_STIC600_1","2zv7","Mus musculus","TYROSINE-PROTEIN KINASE LYN","PF07714(Pkinase_Tyr)",7,"VAL A 261;ALA A 273;GLU A 290;VAL A 303;THR A 319;PHE A 321;ASP A 385","None","0.93A","2hyyC-2zv7A:26.3","2hyyC-2zv7A:46.07"],["2HYY_C_STIC600_1","2zv7","Mus musculus","TYROSINE-PROTEIN KINASE LYN","PF07714(Pkinase_Tyr)",7,"VAL A 261;ALA A 273;VAL A 303;THR A 319;PHE A 321;ALA A 384;ASP A 385","None","0.75A","2hyyC-2zv7A:26.3","2hyyC-2zv7A:46.07"],["2HYY_C_STIC600_1","2zv7","Mus musculus","TYROSINE-PROTEIN KINASE LYN","PF07714(Pkinase_Tyr)",8,"VAL A 261;ALA A 273;VAL A 303;THR A 319;PHE A 321;GLY A 325;LEU A 374;ALA A 384","None","0.83A","2hyyC-2zv7A:26.3","2hyyC-2zv7A:46.07"],["2HYY_C_STIC600_1","3c4f","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",7,"VAL A 492;ALA A 512;GLU A 531;ILE A 538;GLY A 567;LEU A 630;ALA A 640","None;C4F A   1 (-3.3A);None;None;None;C4F A   1 (-4.6A);C4F A   1 (-3.6A)","0.63A","2hyyC-3c4fA:31.7","2hyyC-3c4fA:40.98"],["2HYY_C_STIC600_1","3d7u","Homo sapiens","TYROSINE-PROTEIN KINASE CSK","PF07714(Pkinase_Tyr)",7,"VAL A 209;ALA A 220;GLU A 236;VAL A 249;THR A 266;GLY A 272;LEU A 321","None","0.66A","2hyyC-3d7uA:27.3","2hyyC-3d7uA:44.37"],["2HYY_C_STIC600_1","3dko","Homo sapiens","EPHRIN TYPE-A RECEPTOR 7","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",7,"VAL A 647;ALA A 663;VAL A 695;PHE A 713;GLY A 717;LEU A 765;ASP A 776","IHZ A1001 ( 4.4A);IHZ A1001 (-3.3A);IHZ A1001 ( 4.9A);None;IHZ A1001 ( 3.9A);IHZ A1001 (-4.6A);IHZ A1001 (-4.8A)","0.74A","2hyyC-3dkoA:31.5","2hyyC-3dkoA:35.46"],["2HYY_C_STIC600_1","3hng","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",8,"VAL A 841;ALA A 859;GLU A 878;ILE A 885;VAL A 892;GLY A 915;LEU A1029;ASP A1040","8ST A2001 ( 4.6A);8ST A2001 ( 3.8A);8ST A2001 (-3.7A);None;8ST A2001 ( 4.7A);None;None;None","0.87A","2hyyC-3hngA:33.4","2hyyC-3hngA:33.70"],["2HYY_C_STIC600_1","3iec","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE MARK2","PF00069(Pkinase);PF00627(UBA)",7,"VAL A  67;ALA A  80;VAL A 113;GLY A 135;LEU A 182;ALA A 192;ASP A 193","None","0.85A","2hyyC-3iecA:22.7","2hyyC-3iecA:26.11"],["2HYY_C_STIC600_1","3llt","Plasmodium falciparum","SERINE\/THREONINE KINASE-1, PFLAMMER","PF00069(Pkinase)",7,"VAL A 566;ALA A 579;GLU A 596;ILE A 603;VAL A 614;GLY A 634;LEU A 684","ANP A 877 (-4.1A);ANP A 877 ( 3.7A);ANP A 877 ( 4.4A);None;None;None;None","1.05A","2hyyC-3lltA:21.4","2hyyC-3lltA:22.69"],["2HYY_C_STIC600_1","3mi9","Homo sapiens","CELL DIVISION PROTEIN KINASE 9","PF00069(Pkinase)",7,"VAL A  33;ALA A  46;GLU A  66;VAL A  79;PHE A 105;LEU A 156;ALA A 166","None","0.65A","2hyyC-3mi9A:16.2","2hyyC-3mi9A:25.20"],["2HYY_C_STIC600_1","3my0","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE RECEPTOR R3","PF07714(Pkinase_Tyr)",7,"VAL A 216;ALA A 227;ILE A 245;THR A 277;GLY A 283;ALA A 347;ASP A 348","LDN A 600 (-4.5A);LDN A 600 (-3.2A);None;LDN A 600 (-4.0A);LDN A 600 (-3.3A);LDN A 600 ( 3.8A);None","1.37A","2hyyC-3my0A:25.2","2hyyC-3my0A:28.12"],["2HYY_C_STIC600_1","3my0","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE RECEPTOR R3","PF07714(Pkinase_Tyr)",7,"VAL A 216;ALA A 227;THR A 277;GLY A 283;LEU A 337;ALA A 347;ASP A 348","LDN A 600 (-4.5A);LDN A 600 (-3.2A);LDN A 600 (-4.0A);LDN A 600 (-3.3A);LDN A 600 (-4.6A);LDN A 600 ( 3.8A);None","0.85A","2hyyC-3my0A:25.2","2hyyC-3my0A:28.12"],["2HYY_C_STIC600_1","3niz","Cryptosporidium parvum","RHODANESE FAMILY PROTEIN","PF00069(Pkinase)",7,"VAL A  37;ALA A  49;GLU A  69;VAL A  82;PHE A 100;LEU A 151;ALA A 161","ADP A 314 (-4.0A);ADP A 314 (-3.5A);None;None;ADP A 314 ( 4.3A);ADP A 314 (-4.6A);None","0.77A","2hyyC-3nizA:23.2","2hyyC-3nizA:26.71"],["2HYY_C_STIC600_1","3ppz","Arabidopsis thaliana","SERINE\/THREONINE-PROTEIN KINASE CTR1","PF07714(Pkinase_Tyr)",6,"ALA A 576;GLU A 596;VAL A 609;THR A 625;GLY A 631;LEU A 683","STU A   1 (-3.3A);None;None;STU A   1 (-4.1A);STU A   1 (-3.2A);STU A   1 (-4.3A)","0.51A","2hyyC-3ppzA:29.2","2hyyC-3ppzA:33.55"],["2HYY_C_STIC600_1","3q4t","Homo sapiens","ACTIVIN RECEPTOR TYPE-2A","PF00069(Pkinase)",7,"VAL A 206;ALA A 217;THR A 267;PHE A 269;GLY A 273;LEU A 329;ALA A 339","TAK A   2 ( 4.9A);TAK A   2 (-3.5A);TAK A   2 (-3.5A);TAK A   2 (-4.3A);TAK A   2 (-3.6A);TAK A   2 (-4.6A);TAK A   2 ( 4.2A)","0.61A","2hyyC-3q4tA:24.4","2hyyC-3q4tA:24.62"],["2HYY_C_STIC600_1","3q5i","Plasmodium berghei","PROTEIN KINASE","PF00069(Pkinase);PF13499(EF-hand_7)",7,"VAL A  71;ALA A  84;GLU A 115;THR A 144;PHE A 146;GLY A 150;LEU A 197","ANP A1634 (-4.1A);ANP A1634 (-3.6A);None;ANP A1634 (-4.6A);ANP A1634 (-4.8A);None;ANP A1634 (-4.4A)","0.70A","2hyyC-3q5iA:20.3","2hyyC-3q5iA:22.02"],["2HYY_C_STIC600_1","3tt0","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",7,"VAL A 492;ALA A 512;GLU A 531;ILE A 538;GLY A 567;LEU A 630;ALA A 640","07J A   1 (-4.0A);07J A   1 (-3.5A);07J A   1 (-3.8A);None;07J A   1 (-3.7A);07J A   1 ( 4.4A);07J A   1 (-3.2A)","0.61A","2hyyC-3tt0A:30.9","2hyyC-3tt0A:40.65"],["2HYY_C_STIC600_1","3txo","Homo sapiens","PROTEIN KINASE C ETA TYPE","PF00069(Pkinase);PF00433(Pkinase_C)",7,"ALA A 382;GLU A 403;PHE A 435;GLY A 439;LEU A 486;ALA A 496;ASP A 497","07U A   1 (-3.3A);07U A   1 ( 4.8A);None;None;07U A   1 (-4.3A);07U A   1 ( 4.0A);07U A   1 (-3.6A)","1.19A","2hyyC-3txoA:18.2","2hyyC-3txoA:24.65"],["2HYY_C_STIC600_1","3txo","Homo sapiens","PROTEIN KINASE C ETA TYPE","PF00069(Pkinase);PF00433(Pkinase_C)",7,"ALA A 382;ILE A 406;PHE A 435;GLY A 439;LEU A 486;ALA A 496;ASP A 497","07U A   1 (-3.3A);None;None;None;07U A   1 (-4.3A);07U A   1 ( 4.0A);07U A   1 (-3.6A)","1.11A","2hyyC-3txoA:18.2","2hyyC-3txoA:24.65"],["2HYY_C_STIC600_1","3txo","Homo sapiens","PROTEIN KINASE C ETA TYPE","PF00069(Pkinase);PF00433(Pkinase_C)",7,"VAL A 369;ALA A 382;GLU A 403;PHE A 435;GLY A 439;LEU A 486;ALA A 496","07U A   1 (-4.8A);07U A   1 (-3.3A);07U A   1 ( 4.8A);None;None;07U A   1 (-4.3A);07U A   1 ( 4.0A)","0.82A","2hyyC-3txoA:18.2","2hyyC-3txoA:24.65"],["2HYY_C_STIC600_1","3txo","Homo sapiens","PROTEIN KINASE C ETA TYPE","PF00069(Pkinase);PF00433(Pkinase_C)",7,"VAL A 369;ALA A 382;ILE A 406;PHE A 435;GLY A 439;LEU A 486;ALA A 496","07U A   1 (-4.8A);07U A   1 (-3.3A);None;None;None;07U A   1 (-4.3A);07U A   1 ( 4.0A)","1.08A","2hyyC-3txoA:18.2","2hyyC-3txoA:24.65"],["2HYY_C_STIC600_1","3vid","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",9,"VAL A 848;ALA A 866;GLU A 885;ILE A 892;VAL A 899;PHE A 918;GLY A 922;LEU A1035;ASP A1046","4TT A2001 ( 4.5A);4TT A2001 (-3.5A);None;None;None;4TT A2001 (-4.5A);4TT A2001 (-3.7A);4TT A2001 (-4.8A);None","0.72A","2hyyC-3vidA:30.8","2hyyC-3vidA:34.44"],["2HYY_C_STIC600_1","3wzd","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",8,"VAL A 848;ALA A 866;GLU A 885;ILE A 892;VAL A 899;PHE A 918;GLY A 922;LEU A1035","LEV A1201 ( 4.9A);LEV A1201 (-3.5A);LEV A1201 (-3.7A);None;None;LEV A1201 (-4.7A);LEV A1201 (-3.6A);LEV A1201 (-4.8A)","0.64A","2hyyC-3wzdA:31.9","2hyyC-3wzdA:38.29"],["2HYY_C_STIC600_1","3zdu","Homo sapiens","CYCLIN-DEPENDENT KINASE-LIKE 3","PF00069(Pkinase)",6,"VAL A  18;ALA A  31;GLU A  50;VAL A  63;PHE A  81;LEU A 132","38R A 350 ( 4.8A);38R A 350 (-3.4A);38R A 350 ( 4.8A);38R A 350 ( 4.9A);38R A 350 (-4.2A);38R A 350 (-4.3A)","0.54A","2hyyC-3zduA:22.6","2hyyC-3zduA:26.57"],["2HYY_C_STIC600_1","4agd","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",9,"VAL A 848;ALA A 866;GLU A 885;ILE A 892;VAL A 899;PHE A 918;GLY A 922;LEU A1035;ASP A1046","None;B49 A2000 (-3.5A);None;None;B49 A2000 ( 4.6A);B49 A2000 (-4.4A);B49 A2000 ( 3.7A);B49 A2000 (-4.5A);None","0.80A","2hyyC-4agdA:33.0","2hyyC-4agdA:35.53"],["2HYY_C_STIC600_1","4aw5","Homo sapiens","EPHRIN TYPE-B RECEPTOR 4","PF07714(Pkinase_Tyr)",6,"VAL A 105;ALA A 121;THR A 169;PHE A 171;GLY A 175;LEU A 223","30K A1365 ( 4.6A);30K A1365 (-3.2A);30K A1365 (-3.8A);30K A1365 (-4.4A);30K A1365 (-3.5A);30K A1365 (-4.5A)","0.51A","2hyyC-4aw5A:27.1","2hyyC-4aw5A:39.51"],["2HYY_C_STIC600_1","4bbm","Homo sapiens","CYCLIN-DEPENDENT KINASE-LIKE 2","PF00069(Pkinase)",6,"TYR A  15;VAL A  18;ALA A  31;VAL A  64;PHE A  82;LEU A 133","TC0 A 500 (-4.0A);None;TC0 A 500 (-3.5A);TC0 A 500 (-4.7A);TC0 A 500 (-4.2A);TC0 A 500 (-4.3A)","0.53A","2hyyC-4bbmA:22.2","2hyyC-4bbmA:29.76"],["2HYY_C_STIC600_1","4bc6","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 10","PF00069(Pkinase)",8,"VAL A  50;ALA A  63;GLU A  81;VAL A  94;PHE A 112;GLY A 116;LEU A 164;ALA A 174","XZN A1317 ( 4.7A);XZN A1317 (-3.5A);XZN A1317 (-3.9A);XZN A1317 (-4.4A);XZN A1317 (-4.5A);XZN A1317 ( 3.7A);XZN A1317 (-4.7A);XZN A1317 ( 4.3A)","0.61A","2hyyC-4bc6A:22.1","2hyyC-4bc6A:29.83"],["2HYY_C_STIC600_1","4bc6","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 10","PF00069(Pkinase)",7,"VAL A  50;ALA A  63;ILE A  84;PHE A 112;GLY A 116;LEU A 164;ALA A 174","XZN A1317 ( 4.7A);XZN A1317 (-3.5A);None;XZN A1317 (-4.5A);XZN A1317 ( 3.7A);XZN A1317 (-4.7A);XZN A1317 ( 4.3A)","1.01A","2hyyC-4bc6A:22.1","2hyyC-4bc6A:29.83"],["2HYY_C_STIC600_1","4ckr","Homo sapiens","EPITHELIAL DISCOIDIN DOMAIN-CONTAINING RECEPTOR 1","PF07714(Pkinase_Tyr)",8,"VAL A 624;ALA A 653;GLU A 672;THR A 701;GLY A 707;LEU A 773;ALA A 783;ASP A 784","DI1 A1000 (-4.8A);DI1 A1000 (-3.6A);DI1 A1000 (-3.8A);DI1 A1000 (-3.6A);None;DI1 A1000 (-4.5A);DI1 A1000 (-3.7A);DI1 A1000 (-4.1A)","0.57A","2hyyC-4ckrA:32.2","2hyyC-4ckrA:37.74"],["2HYY_C_STIC600_1","4crs","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE N2","PF00069(Pkinase);PF00433(Pkinase_C)",7,"VAL A 671;ALA A 684;GLU A 705;VAL A 721;GLY A 743;LEU A 789;ALA A 799","AGS A1985 (-4.6A);AGS A1985 (-3.5A);None;None;None;AGS A1985 (-4.8A);AGS A1985 ( 4.5A)","0.61A","2hyyC-4crsA:21.0","2hyyC-4crsA:26.30"],["2HYY_C_STIC600_1","4crs","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE N2","PF00069(Pkinase);PF00433(Pkinase_C)",7,"VAL A 671;ALA A 684;ILE A 708;VAL A 721;GLY A 743;LEU A 789;ALA A 799","AGS A1985 (-4.6A);AGS A1985 (-3.5A);None;None;None;AGS A1985 (-4.8A);AGS A1985 ( 4.5A)","1.01A","2hyyC-4crsA:21.0","2hyyC-4crsA:26.30"],["2HYY_C_STIC600_1","4f0g","Dictyostelium discoideum","SERINE\/THREONINE-PROTEIN KINASE ROCO4","PF07714(Pkinase_Tyr)",7,"VAL A1040;ALA A1053;GLU A1078;VAL A1091;PHE A1107;GLY A1111;ALA A1176","None","0.83A","2hyyC-4f0gA:26.8","2hyyC-4f0gA:30.13"],["2HYY_C_STIC600_1","4fie","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PAK 4","PF00069(Pkinase);PF00786(PBD)",7,"VAL A 335;ALA A 348;GLU A 366;VAL A 379;PHE A 397;GLY A 401;LEU A 447","ANP A1001 (-4.7A);ANP A1001 (-3.6A);ANP A1001 (-3.6A);None;ANP A1001 ( 4.6A);None;ANP A1001 (-4.7A)","0.80A","2hyyC-4fieA:22.3","2hyyC-4fieA:18.42"],["2HYY_C_STIC600_1","4hvi","Homo sapiens","TYROSINE-PROTEIN KINASE JAK3","PF07714(Pkinase_Tyr)",7,"VAL A 836;ALA A 853;GLU A 871;VAL A 884;GLY A 908;LEU A 956;ALA A 966","19S A1201 (-4.4A);19S A1201 (-3.3A);None;None;19S A1201 ( 3.8A);19S A1201 (-4.5A);19S A1201 ( 4.1A)","0.55A","2hyyC-4hviA:30.3","2hyyC-4hviA:34.69"],["2HYY_C_STIC600_1","4k33","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 3","PF07714(Pkinase_Tyr)",7,"VAL A 486;ALA A 506;GLU A 525;ILE A 532;GLY A 561;LEU A 624;ALA A 634","ACP A 801 (-4.2A);ACP A 801 (-3.3A);ACP A 801 ( 4.8A);None;ACP A 801 ( 4.6A);ACP A 801 (-4.4A);None","0.81A","2hyyC-4k33A:26.4","2hyyC-4k33A:39.81"],["2HYY_C_STIC600_1","4lg4","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 3","PF00069(Pkinase)",7,"VAL A  41;ALA A  54;GLU A  70;VAL A  83;GLY A 105;LEU A 153;ALA A 163","GOL A 404 (-4.5A);GOL A 404 ( 3.1A);None;GOL A 403 (-4.1A);GOL A 404 (-3.6A);GOL A 403 ( 4.4A);GOL A 403 ( 3.0A)","1.09A","2hyyC-4lg4A:17.7","2hyyC-4lg4A:24.68"],["2HYY_C_STIC600_1","4o27","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 24","PF00069(Pkinase)",7,"VAL B  38;ALA B  51;GLU B  70;GLY B 105;LEU B 151;ALA B 161;ASP B 162","ADP B 500 (-4.5A);ADP B 500 (-3.3A);None;None;ADP B 500 (-4.7A);None;ADP B 500 ( 3.4A)","0.89A","2hyyC-4o27B:18.4","2hyyC-4o27B:29.33"],["2HYY_C_STIC600_1","4o38","Homo sapiens","CYCLIN-G-ASSOCIATED KINASE","PF00069(Pkinase)",7,"ALA A  67;GLU A  85;VAL A  99;THR A 123;GLY A 128;LEU A 180;ASP A 191","SIN A 401 ( 3.7A);None;None;None;SIN A 401 (-3.5A);SIN A 401 ( 4.5A);None","0.95A","2hyyC-4o38A:19.7","2hyyC-4o38A:24.56"],["2HYY_C_STIC600_1","4o38","Homo sapiens","CYCLIN-G-ASSOCIATED KINASE","PF00069(Pkinase)",7,"VAL A  54;ALA A  67;GLU A  85;VAL A  99;THR A 123;GLY A 128;LEU A 180","None;SIN A 401 ( 3.7A);None;None;None;SIN A 401 (-3.5A);SIN A 401 ( 4.5A)","0.63A","2hyyC-4o38A:19.7","2hyyC-4o38A:24.56"],["2HYY_C_STIC600_1","4rt7","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",7,"VAL A 624;ALA A 642;GLU A 661;VAL A 675;GLY A 697;LEU A 818;ASP A 829","None;P30 A1001 (-3.4A);P30 A1001 (-3.6A);None;P30 A1001 (-3.4A);P30 A1001 (-4.6A);None","0.63A","2hyyC-4rt7A:29.0","2hyyC-4rt7A:33.68"],["2HYY_C_STIC600_1","4ueu","synthetic construct","TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL","PF07714(Pkinase_Tyr)",7,"VAL A  22;ALA A  35;ILE A  55;THR A  81;GLY A  87;LEU A 136;ALA A 146","ACP A1264 (-4.7A);ACP A1264 (-2.9A);None;ACP A1264 (-4.5A);ACP A1264 (-3.5A);ACP A1264 ( 4.8A);None","1.23A","2hyyC-4ueuA:33.2","2hyyC-4ueuA:66.42"],["2HYY_C_STIC600_1","4ueu","synthetic construct","TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL","PF07714(Pkinase_Tyr)",7,"VAL A  22;ALA A  35;ILE A  55;THR A  81;LEU A 136;ALA A 146;ASP A 147","ACP A1264 (-4.7A);ACP A1264 (-2.9A);None;ACP A1264 (-4.5A);ACP A1264 ( 4.8A);None;None","1.18A","2hyyC-4ueuA:33.2","2hyyC-4ueuA:66.42"],["2HYY_C_STIC600_1","4ueu","synthetic construct","TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL","PF07714(Pkinase_Tyr)",7,"VAL A  22;ALA A  35;VAL A  65;THR A  81;GLY A  87;LEU A 136;ALA A 146","ACP A1264 (-4.7A);ACP A1264 (-2.9A);None;ACP A1264 (-4.5A);ACP A1264 (-3.5A);ACP A1264 ( 4.8A);None","0.58A","2hyyC-4ueuA:33.2","2hyyC-4ueuA:66.42"],["2HYY_C_STIC600_1","4ueu","synthetic construct","TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL","PF07714(Pkinase_Tyr)",7,"VAL A  22;ALA A  35;VAL A  65;THR A  81;LEU A 136;ALA A 146;ASP A 147","ACP A1264 (-4.7A);ACP A1264 (-2.9A);None;ACP A1264 (-4.5A);ACP A1264 ( 4.8A);None;None","0.76A","2hyyC-4ueuA:33.2","2hyyC-4ueuA:66.42"],["2HYY_C_STIC600_1","4usf","Homo sapiens","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","PF00069(Pkinase)",8,"VAL A  48;ALA A  61;VAL A  92;PHE A 110;GLY A 114;LEU A 162;ALA A 172;ASP A 173","None;6UI A 700 (-3.3A);None;6UI A 700 (-4.3A);6UI A 700 ( 4.2A);6UI A 700 (-4.2A);6UI A 700 ( 4.1A);None","0.97A","2hyyC-4usfA:25.0","2hyyC-4usfA:28.00"],["2HYY_C_STIC600_1","4wsq","Homo sapiens","AP2-ASSOCIATED PROTEIN KINASE 1","PF00069(Pkinase)",7,"ALA A  72;GLU A  90;VAL A 104;PHE A 128;GLY A 132;LEU A 183;ASP A 194","KSA A 405 (-3.2A);None;None;KSA A 405 (-4.8A);KSA A 405 (-3.5A);KSA A 405 (-4.6A); ZN A 403 ( 2.6A)","0.96A","2hyyC-4wsqA:23.0","2hyyC-4wsqA:23.46"],["2HYY_C_STIC600_1","4wsq","Homo sapiens","AP2-ASSOCIATED PROTEIN KINASE 1","PF00069(Pkinase)",7,"VAL A  60;ALA A  72;GLU A  90;VAL A 104;PHE A 128;GLY A 132;LEU A 183","KSA A 405 ( 4.9A);KSA A 405 (-3.2A);None;None;KSA A 405 (-4.8A);KSA A 405 (-3.5A);KSA A 405 (-4.6A)","0.62A","2hyyC-4wsqA:23.0","2hyyC-4wsqA:23.46"],["2HYY_C_STIC600_1","4xbr","Homo sapiens","PROTEIN FAM212A,SERINE\/THREONINE-PROTEIN KINASE PAK 4","PF00069(Pkinase);PF15342(FAM212)",7,"VAL A 335;ALA A 348;GLU A 366;VAL A 379;PHE A 397;GLY A 401;LEU A 447","ATP A 601 (-4.4A);ATP A 601 ( 3.7A);ATP A 601 ( 3.7A);None;ATP A 601 (-4.6A);None;None","0.81A","2hyyC-4xbrA:16.6","2hyyC-4xbrA:21.58"],["2HYY_C_STIC600_1","4xcu","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 4","PF07714(Pkinase_Tyr)",7,"VAL A 481;ALA A 501;GLU A 520;ILE A 527;GLY A 556;LEU A 619;ALA A 629","40M A1002 ( 4.5A);40M A1002 ( 4.1A);40M A1002 (-3.7A);None;40M A1002 ( 3.7A);40M A1002 (-4.5A);40M A1002 (-3.0A)","0.74A","2hyyC-4xcuA:31.4","2hyyC-4xcuA:40.47"],["2HYY_C_STIC600_1","4xey","Homo sapiens","TYROSINE-PROTEIN KINASE ABL1","no annotation",9,"VAL B 275;ALA B 288;ILE B 312;VAL B 318;THR B 334;PHE B 336;GLY B 340;LEU B 389;ALA B 399","1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);None;1N1 B 601 ( 4.3A);1N1 B 601 (-3.3A);1N1 B 601 ( 4.2A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.69A","2hyyC-4xeyB:36.1","2hyyC-4xeyB:100.00"],["2HYY_C_STIC600_1","4xuf","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",7,"VAL A 624;ALA A 642;GLU A 661;VAL A 675;GLY A 697;LEU A 818;ASP A 829","P30 A1001 ( 4.8A);P30 A1001 (-3.5A);P30 A1001 (-3.1A);None;P30 A1001 (-3.5A);P30 A1001 (-4.3A);None","0.51A","2hyyC-4xufA:33.9","2hyyC-4xufA:38.39"],["2HYY_C_STIC600_1","4yff","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE TNNI3K","PF07714(Pkinase_Tyr)",7,"VAL A 477;ALA A 488;GLU A 509;THR A 539;GLY A 545;LEU A 595;ALA A 605","None;4CV A 801 (-3.5A);None;4CV A 801 (-2.8A);4CV A 801 ( 4.0A);4CV A 801 (-4.4A);4CV A 801 ( 3.9A)","0.65A","2hyyC-4yffA:25.5","2hyyC-4yffA:29.30"],["2HYY_C_STIC600_1","5a46","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","PF07714(Pkinase_Tyr)",7,"VAL A 492;ALA A 512;GLU A 531;ILE A 538;GLY A 567;LEU A 630;ALA A 640","38O A1769 (-4.5A);38O A1769 (-3.6A);EDO A1766 (-4.1A);None;38O A1769 (-3.4A);38O A1769 (-4.6A);EDO A1766 ( 4.4A)","0.72A","2hyyC-5a46A:30.6","2hyyC-5a46A:40.76"],["2HYY_C_STIC600_1","5ci7","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE ULK1","PF00069(Pkinase)",6,"VAL A  30;ALA A  44;VAL A  76;GLY A  98;LEU A 145;ALA A 164","51W A 401 ( 4.3A);51W A 401 (-3.4A);None;51W A 401 (-3.7A);51W A 401 (-4.5A);None","0.50A","2hyyC-5ci7A:23.2","2hyyC-5ci7A:28.19"],["2HYY_C_STIC600_1","5e8y","Homo sapiens","TGF-BETA RECEPTOR TYPE-2","PF07714(Pkinase_Tyr)",7,"VAL A 258;ALA A 275;GLU A 290;THR A 325;PHE A 327;GLY A 331;LEU A 386","STU A 601 (-4.0A);STU A 601 (-3.1A);STU A 601 ( 3.8A);STU A 601 ( 3.7A);STU A 601 (-3.4A);STU A 601 (-3.5A);STU A 601 (-3.9A)","0.72A","2hyyC-5e8yA:19.0","2hyyC-5e8yA:27.27"],["2HYY_C_STIC600_1","5es1","Homo sapiens","MAP\/MICROTUBULE AFFINITY-REGULATING KINASE 4","PF00069(Pkinase);PF00627(UBA)",7,"VAL A  70;ALA A  83;GLU A 103;VAL A 116;GLY A 138;LEU A 185;ALA A 195","5RC A4000 (-4.6A);5RC A4000 (-3.6A);None;None;5RC A4000 (-3.3A);None;5RC A4000 ( 3.9A)","0.94A","2hyyC-5es1A:11.0","2hyyC-5es1A:25.60"],["2HYY_C_STIC600_1","5eyk","Xenopus laevis","AURORA KINASE B-A","PF00069(Pkinase)",7,"VAL A 107;ALA A 120;PHE A 172;GLY A 176;LEU A 223;ALA A 233;ASP A 234","5U5 A 401 ( 4.3A);5U5 A 401 (-3.5A);5U5 A 401 (-4.5A);5U5 A 401 (-3.4A);5U5 A 401 (-4.7A);None;None","0.81A","2hyyC-5eykA:17.7","2hyyC-5eykA:25.50"],["2HYY_C_STIC600_1","5grn","Homo sapiens","PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA","PF07714(Pkinase_Tyr)",8,"VAL A 607;ALA A 625;GLU A 644;VAL A 658;THR A 674;GLY A 680;LEU A 825;ASP A 836","748 A1001 ( 4.7A);748 A1001 (-3.7A);748 A1001 (-3.3A);748 A1001 ( 4.8A);748 A1001 (-3.2A);748 A1001 ( 4.0A);748 A1001 (-4.3A);748 A1001 (-4.8A)","0.61A","2hyyC-5grnA:29.6","2hyyC-5grnA:36.81"],["2HYY_C_STIC600_1","5gz8","Mus musculus","PROTEIN O-MANNOSE KINASE","PF07714(Pkinase_Tyr)",6,"VAL A  94;ALA A 105;VAL A 134;THR A 148;GLY A 154;LEU A 215","None","0.34A","2hyyC-5gz8A:19.4","2hyyC-5gz8A:23.36"],["2HYY_C_STIC600_1","5hu3","Drosophila melanogaster","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE II ALPHA CHAIN","PF00069(Pkinase)",7,"VAL A  28;ALA A  41;GLU A  61;VAL A  74;GLY A  96;LEU A 143;ALA A 156","ADP A 301 (-3.7A);ADP A 301 (-3.5A);None;None;None;ADP A 301 (-4.7A);ADP A 301 ( 4.8A)","0.60A","2hyyC-5hu3A:23.4","2hyyC-5hu3A:26.09"],["2HYY_C_STIC600_1","5j5t","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3","PF00069(Pkinase)",8,"VAL A  30;ALA A  43;GLU A  61;VAL A  74;PHE A  92;GLY A  96;LEU A 143;ALA A 153","6G2 A 901 ( 4.9A);6G2 A 901 (-3.2A);None;None;6G2 A 901 (-4.1A);6G2 A 901 (-3.6A);6G2 A 901 (-4.7A);6G2 A 901 ( 4.2A)","0.59A","2hyyC-5j5tA:21.9","2hyyC-5j5tA:24.12"],["2HYY_C_STIC600_1","5lpy","Arabidopsis thaliana","PROTEIN BRASSINOSTEROID INSENSITIVE 1","PF00069(Pkinase)",7,"VAL A 897;ALA A 909;GLU A 927;VAL A 940;PHE A 958;GLY A 962;LEU A1016","ATP A1200 ( 4.5A);ATP A1200 (-3.5A);None;None;ATP A1200 ( 4.0A);ATP A1200 ( 4.0A);ATP A1200 (-4.6A)","0.63A","2hyyC-5lpyA:23.2","2hyyC-5lpyA:30.49"],["2HYY_C_STIC600_1","5lpz","Arabidopsis thaliana","PROTEIN BRASSINOSTEROID INSENSITIVE 1","PF00069(Pkinase)",7,"VAL A 897;ALA A 909;GLU A 927;VAL A 940;PHE A 958;GLY A 962;LEU A1016","ADP A1200 (-4.4A);ADP A1200 (-3.5A);None;None;ADP A1200 (-4.1A);ADP A1200 ( 4.0A);ADP A1200 (-4.7A)","0.69A","2hyyC-5lpzA:23.2","2hyyC-5lpzA:29.22"],["2HYY_C_STIC600_1","5u7q","Homo sapiens","RHO-ASSOCIATED PROTEIN KINASE 2","PF00069(Pkinase)",7,"ALA A 119;ILE A 143;VAL A 153;GLY A 174;LEU A 221;ALA A 231;ASP A 232","None","1.20A","2hyyC-5u7qA:18.6","2hyyC-5u7qA:23.13"],["2HYY_C_STIC600_1","5u7q","Homo sapiens","RHO-ASSOCIATED PROTEIN KINASE 2","PF00069(Pkinase)",7,"ALA A 119;ILE A 143;VAL A 153;GLY A 175;LEU A 221;ALA A 231;ASP A 232","None","1.09A","2hyyC-5u7qA:18.6","2hyyC-5u7qA:23.13"],["2HYY_C_STIC600_1","5u7q","Homo sapiens","RHO-ASSOCIATED PROTEIN KINASE 2","PF00069(Pkinase)",7,"VAL A 106;ALA A 119;GLU A 140;VAL A 153;GLY A 175;LEU A 221;ALA A 231","None","0.93A","2hyyC-5u7qA:18.6","2hyyC-5u7qA:23.13"],["2HYY_C_STIC600_1","5u7q","Homo sapiens","RHO-ASSOCIATED PROTEIN KINASE 2","PF00069(Pkinase)",7,"VAL A 106;ALA A 119;ILE A 143;VAL A 153;GLY A 175;LEU A 221;ALA A 231","None","1.00A","2hyyC-5u7qA:18.6","2hyyC-5u7qA:23.13"],["2HYY_C_STIC600_1","5vef","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PAK 4","no annotation",7,"VAL A 335;ALA A 348;GLU A 366;VAL A 379;PHE A 397;GLY A 401;LEU A 447","M77 A 601 (-4.5A);M77 A 601 ( 3.5A);None;None;M77 A 601 (-4.1A);M77 A 601 ( 4.8A);M77 A 601 (-4.6A)","0.77A","2hyyC-5vefA:22.8","2hyyC-5vefA:21.75"],["2HYY_C_STIC600_1","5vil","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 5","no annotation",6,"VAL A 694;ALA A 707;GLU A 725;VAL A 738;GLY A 760;LEU A 810","9E1 A1001 ( 4.0A);9E1 A1001 (-3.5A);None;9E1 A1001 (-4.1A);9E1 A1001 (-3.4A);9E1 A1001 (-4.5A)","0.53A","2hyyC-5vilA:19.3","2hyyC-5vilA:15.30"]]